|Bid||0.00 x 12000|
|Ask||0.00 x 12000|
|Day's range||15.85 - 15.90|
|52-week range||15.31 - 49.99|
|Beta (5Y monthly)||1.57|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2022 - 25 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||22.80|
CAMBRIDGE, Mass., November 22, 2021--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel) for priority review. Beti-cel is a potentially transformative gene therapy for adult, adolescent and pediatric patients with β-thalassemia across all genotypes who require regular red blood cell (RBC) transfusions. If approved, beti-cel will be the first one-time treatme
If you want to know who really controls bluebird bio, Inc. ( NASDAQ:BLUE ), then you'll have to look at the makeup of...
CAMBRIDGE, Mass., November 05, 2021--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2021.